N. Sin

发表

The alkylation of isatin‐derived oximes: Spectroscopic and X‐ray crystallographic structural characterization of oxime and nitrone products

Stella Huang, N. Meanwell, R. Dalterio, 2009 .

Maturation Inhibitor with Improved Potency, Anti-viral Spectrum and Gag Polymorphic

N. Meanwell, Zeyu Lin, M. Krystal, 2016 .

Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage

N. Meanwell, Zeyu Lin, M. Krystal, 2016, Antimicrobial Agents and Chemotherapy.

Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity.

B. Beno, N. Meanwell, Zeyu Lin, 2016, ACS medicinal chemistry letters.

15N chemical shifts of a series of isatin oxime ethers and their corresponding nitrone isomers

V. Roongta, N. Sin, B. Venables, 2010, Magnetic resonance in chemistry : MRC.

Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

C. Crews, B. Kwok, M. Elofsson, 1999, Bioorganic & medicinal chemistry letters.

Diastereoselective [2,3] Wittig rearrangement of carbohydrate-derived tertiary allylic ethers. 2. Synthesis of an advanced rapamycin intermediate from D-glucose.

N. Sin, J. Kallmerten, 1993 .

Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.

L. Mueller, K. Kish, H. Klei, 2016, Journal of medicinal chemistry.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.

C. Crews, B. Kwok, M. Elofsson, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

C. Crews, B. Kwok, M. Elofsson, 1999, Bioorganic & medicinal chemistry letters.

Eponemycin exerts its antitumor effect through the inhibition of proteasome function.

C. Crews, B. Kwok, B H Kwok, 1999, Cancer research.

Eponemycin analogues: syntheses and use as probes of angiogenesis.

C. Crews, N. Sin, L. Meng, 1998, Bioorganic & medicinal chemistry.

The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.

Qi Gao, Huabin Sun, Hong Shi, 2014, Journal of medicinal chemistry.

Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.

A. Marino, N. Meanwell, I. Medina, 2007, Bioorganic & medicinal chemistry letters.

Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection

N. Meanwell, I. Medina, C. Cianci, 2004, Antimicrobial Agents and Chemotherapy.

Orally Active Fusion Inhibitor of Respiratory Syncytial Virus

N. Meanwell, I. Medina, C. Cianci, 2004, Antimicrobial Agents and Chemotherapy.

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.

W. Bornmann, C. Crews, C M Crews, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo.

A. Marino, N. Meanwell, I. Medina, 2009, Bioorganic & medicinal chemistry letters.

Synthesis of (2S,3S,8S,9S)-Adda from D-glucose

N. Sin, J. Kallmerten, 1996 .

P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.

A. Good, N. Meanwell, R. Rajamani, 2018, Bioorganic & medicinal chemistry letters.

Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,1

B. Beno, N. Meanwell, V. Arora, 2018, Journal of medicinal chemistry.

The use of IR spectroscopy to monitor the conversion of matrix isolated phenylacetyl chloride to phenylacetyl cation, without decarbonylation to benzyl cation

T. Ramsey, N. Sin, R. Jarret, 1989 .

The design, synthesis and structure-activity relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation.

N. Meanwell, Zeyu Lin, M. Krystal, 2018, Bioorganic & medicinal chemistry letters.

Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.

C. Crews, K. Kim, N. Sin, 1999, Bioorganic & medicinal chemistry letters.

Inhibitors of HIV-1 maturation: Development of structure-activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids.

N. Meanwell, M. Krystal, Tricia L. Protack, 2016, Bioorganic & medicinal chemistry letters.

The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.

A. Mathur, N. Meanwell, Zeyu Lin, 2022, Journal of medicinal chemistry.

Deuterium Isotope Effects on13C NMR Chemical Shifts of Amides

N. Sin, R. Jarret, Matthew R. Dintzner, 1997 .

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.